DBV Technologies | DBVT - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 243.27M 14.49M 2026-03
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amarin USD 23.17M 961K 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
DBV Technologies USD 2.77M 33.21M 2025-09
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Incyte USD 1.17B 217.51M 2026-03
Insmed USD 256.46M 38.78M 2026-03
Ionis Pharmaceuticals USD 243M 48M 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
PTC Therapeutics USD 232.94M 84.56M 2026-03
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
Ultragenyx Pharmaceutical USD 106M 72M 2026-03
United Therapeutics USD 315.5M 286.6M 2025-12